Myelofibrosis
Not recruitingStudy of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment
- Disease:Myelofibrosis
- Substances:Alkylating agentsAntimetabolites+1
Bulgaria- Participants:18–64 years · 65+ years
- Substances:Alkylating agents
- Sponsor:Geron Corp.















